Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital

Describe the use of tofacitinib in severe and critical coronavirus disease-2019 (COVID-19), and explore the association of drug initiation time with survival. A retrospective study of inpatients with severe or critical COVID-19 at a tertiary care hospital, who were prescribed generic tofacitinib for...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodali, Ramya, Umesh, Soumya, Selvam, Sumithra, Kamath, Deepak, Shobha, Vineeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622334/
https://www.ncbi.nlm.nih.gov/pubmed/36316872
http://dx.doi.org/10.1097/MD.0000000000030975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622334/
https://www.ncbi.nlm.nih.gov/pubmed/36316872
http://dx.doi.org/10.1097/MD.0000000000030975

Ejemplares similares